Newpath Partners
Venture capitalActively deployingBoston · Seed–Series A · 3 people tracked
Also known as NEWPATH MANAGEMENT, L.P.
Investment thesis
Led by physician-scientist Tom Cahill, they form companies from academic discoveries in gene editing and regenerative medicine, offering company-formation expertise, board experience, and a high formation-and-exit track record.
Source: firm website, verified Aug 25, 2026.
Team · 3 people
from public directories
What they invest in
from 19 of 20 portfolio companiesBiotech ×16Medical Devices ×15Deep Tech ×6Healthtech ×6AI & Machine Learning ×4Digital Health ×3Marketing Tech ×1Retail Tech ×1
HQs:United States×11
Investments · 20 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22024 · 12023 · 32022 · 12021 · 12020 · 110 dated
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)David Liu(Co-founder)Allan Reine(Chief Executive Officer)Mohammed Asmal(Chief Medical Officer)Ann Lee(Chief Technical Officer)Svetlana Makhni(Chief Financial Officer)
Co-investorsARCH Venture PartnersGV (Google Ventures)F-Prime CapitalOUP (Osage University Partners)Samsara BioCapital
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)Kari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
BoardKristina Burow(Director)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier Partners+1 more
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuAlan Saghetelian
Co-investorsCRV (Charles River Ventures)Nextech InvestRaptor GroupSamsara BioCapitalCasdin CapitalNovartis Venture Fund
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical Devices
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)
Co-investorsARCH Venture PartnersTaiho Ventures, LLC
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Co-investorsAtlas VentureARCH Venture PartnersDCVC (Data Collective)F-Prime Capital5AM VenturesDCVC Bio+1 more
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)
BoardKristina Burow(Director)inTimothy Anderson(Director)Philip J DeSouza(Director)
Board seatThomas Cahill· per SEC Form D
Co-investorsARCH Venture PartnersCanaan PartnersMonograph Capital PartnersPfizer Venture InvestmentsSamsara BioCapital
Travel & HospitalityHouston, US
Andrew C. Levy(Chief Executive Officer)Hunter Keay(Chief Financial Officer)Robert Ashcroft(Director)Miguel Heras(Director)
BoardWill Snellings(Director)Thomas Mahr(Director)
Board seatThomas Cahill· per SEC Form D · $40M raise · filed Jan 2025
Co-investorsMorgan Stanley
Boston, US
Board seatThomas Cahill· per SEC Form D · $135M raise · filed Sep 2023
Co-investorsAtlas Venture
DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
BiotechDigital HealthMedical DevicesBoston, US
Robert Brucker(Executive Officer)Karl R. Beutner(Executive Officer, Director)Nichola Eliovits(Executive Officer, Director)inMax Dawson(Executive Officer)
BoardWilder Ramsey(Director)inJennifer Lee(Director)
Board seatDaniel Yadegar· per SEC Form D · $45.3M raise · filed Nov 2024
Co-investorsCivilization Ventures Management, LlcJoyance PartnersOlive Tree CapitalStart CapitalToba CapitalValia Ventures
BiotechBoston, US
Nagesh Mahanthappa, Ph.D.(Director)Luba Greenwood(Director)
BoardAmir Nashat, Ph.D.(Treasurer and Secretary)Susan Langer(President)
Board seatThomas J. Cahill· per SEC Form D · $60.2M raise · filed Jun 2021
BiotechBoston, US
Nichola Eliovits(Executive Officer, Director)Max Dawson(Executive Officer)Karl Beutner(Executive Officer, Director)
Board seatDaniel Yadegar· per SEC Form D · $2.5M raise · filed Oct 2025
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
Feng Zhang, Ph.D.(Scientific Founder & Board Observer)Akin Akinc, Ph.D.(Chief Executive Officer & Board Director)
Co-investorsARCH Venture PartnersLux CapitalF-Prime CapitalGV (Google Ventures)JDRF T1D Fund
YourBio Health develops the TAP Device with HALO technology, a needle-free blood collection system that uses micro-needles thinner than an eyelash to enable virtually painless blood draws.
HealthtechMedical Devices
Co-investorsRaptor Group
CREATE Medicines is a clinical-stage biotech company that develops in vivo mRNA immune cell programming therapies.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Daniel Getts(Founder and CEO)inBrett Kaplan(Chief Financial and Business Officer)inMarcus Lowe(Executive Officer, Director)Dhruv Amin(Executive Officer, Director)
Co-investors8VCRaptor Group
Eledon develops tegoprubart, an anti-CD40L antibody in clinical development for preventing rejection in organ transplant recipients.
BiotechMedical Devices
Steven Perrin(President and Chief Scientific Officer)
Co-investorsJDRF T1D Fund
Leal 360 is a retail-focused customer platform for LATAM that combines a CDP, campaign automation, loyalty programs, and NPS with an AI decision engine, connecting to a business's POS to turn purchase data into personalized marketing and loyalty actions.
AI & Machine LearningMarketing TechRetail Tech
Co-investorsAspira CapitalAxon Partners GroupCapria VenturesFuel Venture CapitalLEAP Global PartnersSalkantay Ventures+1 more
Leal Therapeutics develops first-in-class neuro-metabolic therapeutics for central nervous system disorders, including oral small molecules and antisense oligonucleotides targeting metabolic pathways underlying neuropsychiatric and neurodegenerative diseases such as schizophrenia, ALS, and Alzheimer's.
BiotechMedical DevicesWorcester, US
Co-investorsOrbiMed
Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.
BiotechHealthtechMedical DevicesNew York, US
Christopher J. Visioli(Executive Officer)Brian Hubbard(Executive Officer)Christopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)Clive A. Meanwell(Director)Paul L. Berns(Director)
Co-investorsAlpha Wave GlobalARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalSoftBank Vision Fund
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.
AI & Machine LearningBiotechHealthtechMedical Devices
Co-investorsARCH Venture Partners8VCHatteras Venture Partners
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersAgent Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
IPOs and acquisitions across the tracked portfolioPrime MedicineNASDAQ: PRMENeumora TherapeuticsNASDAQ: NMRAMetseraacq. by Pfizer
Portfolio news
latest coverage across their companies
Leal · dot.la · Aug 21, 2026
Neumora Therapeutics · dailypolitical.com · Jul 16, 2026
nChroma Bio · contagionlive.com · Jun 25, 2026
Myeloid Therapeutics · trial.medpath.com · May 15, 2026
Aera Therapeutics · ainvest.com · Mar 22, 2026
Avelo · prnewswire.com · Sep 8, 2025
Orbital Therapeutics · trysignalbase.com · Aug 3, 2025
Frequently asked questions
- What stage does Newpath Partners invest at?
- Newpath Partners invests at the Seed, Series A stages.
- What is Newpath Partners's typical check size?
- Newpath Partners typically writes checks of $50K – $10M.
- What sectors does Newpath Partners focus on?
- Newpath Partners focuses on Biotech, Medical Devices.
- Where is Newpath Partners located?
- Newpath Partners is headquartered in Boston, US.
- Does Newpath Partners lead rounds?
- Newpath Partners typically participates in rounds rather than leading them.
Images
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.